If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

AGM Statement

8 Sep 2011 07:00

RNS Number : 8405N
Immunodiagnostic Systems Hldgs PLC
08 September 2011
 



 

 

Immunodiagnostic Systems Holdings plc

("IDS" or "the Company")

 

AGM Statement

 

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, will hold its Annual General Meeting today at 3.00pm at the offices of Brewin Dolphin Limited at 12 Smithfield Street, London EC1A 9BD.

 

At the meeting Chairman, David Evans, will make the following statement to shareholders:

 

"Revenues to 31 August are £22.6m compared with £18.4m for the comparative period in 2010. We have seen continued growth in our IDS-iSYS revenues which have grown £4.4m over the comparative period. As of 31 August 299 instruments have been sold or placed an increase of 58 systems since the year end and we anticipate a further 15 instruments being placed or sold in September. Average revenue per instrument is £88k compared to £72k in August 2010.

 

Our revenues are traditionally weighted to the second-half of the year and we believe this year that the trend ratio will be higher this financial year reflecting both a seasonally quieter July and August and also higher anticipated reagent / instrument sales pull-through and the anticipated continued resilience of manual product sales in the second-half.

 

The process of transition in terms of the Board has continued since the year end. We have added Roland Sackers, the CFO of QIAGEN N.V. and at the end of this meeting Anthony Martin, who has a long-established track record in the diagnostics and life sciences space, will succeed me as Chairman.

We remain active in examining the potential for licensing-out our automated IDS-iSYS platform into other disease areas not served by the Company and which can help drive value. We have ongoing discussions in autoimmune disease and in coagulation testing outside of Europe and we will keep you updated as discussions progress.

 

Finally we continue to seek acquisitions where we believe we can either add value to our existing franchise in bone and mineral disease or where we can validly exploit the IDS-iSYS asset base.

 

A more detailed trading update will be given week commencing 3rd October."

 

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel: 0191 519 0660

Ian Cookson, Chief Executive Officer

Paul Hailes, Finance Director

 

 

 

Brewin Dolphin

Tel: 0845 213 4930

Matt Davis

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSSAFWWFFSEFU
Date   Source Headline
29th Oct 20077:00 amRNSNotice of Results
5th Oct 200712:11 pmRNSNotifiable Interest
2nd Oct 20077:01 amRNSSenior Management Appointment
17th Sep 20073:33 pmRNSNotifiable Interest
17th Sep 20077:01 amRNSBoard Appointment
10th Sep 20073:48 pmRNSNotifiable Interest
3rd Sep 20077:01 amRNSTotal Voting Rights
3rd Sep 20077:00 amRNSCompletion of Acquisition
31st Aug 20073:16 pmRNSAGM Statement
28th Aug 20071:48 pmRNSResult of EGM
20th Aug 200712:36 pmRNSNotifiable Interest
20th Aug 20079:53 amRNSAIM Rule 26
3rd Aug 20077:00 amRNSProposed Acquisition
31st Jul 200711:03 amRNSTotal Voting Rights
26th Jul 20077:01 amRNSCompletion of acquisition
16th Jul 20075:57 pmRNSCorrection re. dividend dates
16th Jul 20077:01 amRNSFinal Results
29th Jun 20077:01 amRNSNotice of Results
18th Jun 20077:02 amRNSImmunoassay kits agreement
8th May 20077:01 amRNSNotifiable Interest
3rd May 20073:39 pmRNSDirectors Dealing
21st Mar 20077:00 amRNSTrading Statement
20th Mar 20075:33 pmRNSNotifiable Interest
13th Mar 20077:00 amRNSBoard Appointment
12th Feb 20077:02 amRNSBoard Appointment
31st Jan 20077:02 amRNSProduct launch
4th Jan 20077:00 amRNSProduct Launch
21st Dec 200612:48 pmRNSTotal Voting Rights
5th Dec 20069:44 amRNSDirector/PDMR Shareholding
4th Dec 20067:02 amRNSAutomation agreement
15th Nov 20068:54 amRNSHolding(s) in Company
6th Nov 20067:01 amRNSInterim Results
19th Oct 200611:34 amRNSNotice of Results
10th Oct 20067:02 amRNSIDS launches into Austria
13th Sep 20067:00 amRNSLaunch of new assay kit
22nd Aug 200611:04 amRNSAGM Statement
17th Jul 20064:35 pmRNSHolding(s) in Company
5th Jul 20067:00 amRNSFinal Results
30th May 20067:03 amRNSMarketing & sales agreement
15th May 20067:01 amRNSDirectorate Change
12th Apr 20067:01 amRNSDirector/PDMR Shareholding
30th Mar 20067:01 amRNSPre-close Trading update
21st Feb 20062:38 pmRNSDirectors Dealing
7th Nov 20057:00 amRNSInterim Results
26th Oct 20059:52 amRNSNotice of Results
26th Sep 20057:01 amRNSBoard Appointment
6th Sep 200511:18 amRNSAGM Statement
12th Aug 200510:42 amRNSFDA Approval
12th Jul 20057:01 amRNSFinal Results
6th Jul 20053:19 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.